Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Place of Gamma Knife Stereotactic Radiosurgery in Grade 4 Vestibular Schwannoma Based on Case Series of 86 Patients with Long-Term Follow-Up.

Lefranc M, Da Roz LM, Balossier A, Thomassin JM, Roche PH, Regis J.

World Neurosurg. 2018 Mar 31. pii: S1878-8750(18)30657-0. doi: 10.1016/j.wneu.2018.03.175. [Epub ahead of print]

PMID:
29614352
2.

MiR-16 regulates the pro-tumorigenic potential of lung fibroblasts through the inhibition of HGF production in an FGFR-1- and MEK1-dependent manner.

Andriani F, Majorini MT, Mano M, Landoni E, Miceli R, Facchinetti F, Mensah M, Fontanella E, Dugo M, Giacca M, Pastorino U, Sozzi G, Delia D, Roz L, Lecis D.

J Hematol Oncol. 2018 Mar 20;11(1):45. doi: 10.1186/s13045-018-0594-4.

3.

Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors.

George J, Walter V, Peifer M, Alexandrov LB, Seidel D, Leenders F, Maas L, Müller C, Dahmen I, Delhomme TM, Ardin M, Leblay N, Byrnes G, Sun R, De Reynies A, McLeer-Florin A, Bosco G, Malchers F, Menon R, Altmüller J, Becker C, Nürnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soloway MG, Wilkerson MD, Cun Y, McKay JD, Moro-Sibilot D, Brambilla CG, Lantuejoul S, Lemaitre N, Soltermann A, Weder W, Tischler V, Brustugun OT, Lund-Iversen M, Helland Å, Solberg S, Ansén S, Wright G, Solomon B, Roz L, Pastorino U, Petersen I, Clement JH, Sänger J, Wolf J, Vingron M, Zander T, Perner S, Travis WD, Haas SA, Olivier M, Foll M, Büttner R, Hayes DN, Brambilla E, Fernandez-Cuesta L, Thomas RK.

Nat Commun. 2018 Mar 13;9(1):1048. doi: 10.1038/s41467-018-03099-x.

4.

Author Correction: Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness.

Moro M, Bertolini G, Caserini R, Borzi C, Boeri M, Fabbri A, Leone G, Gasparini P, Galeone C, Pelosi G, Roz L, Sozzi G, Pastorino U.

Sci Rep. 2018 Feb 27;8(1):3965. doi: 10.1038/s41598-018-21279-z.

5.

Complement C4d-specific antibodies for the diagnosis of lung cancer.

Ajona D, Okrój M, Pajares MJ, Agorreta J, Lozano MD, Zulueta JJ, Verri C, Roz L, Sozzi G, Pastorino U, Massion PP, Montuenga LM, Blom AM, Pio R.

Oncotarget. 2017 Dec 26;9(5):6346-6355. doi: 10.18632/oncotarget.23690. eCollection 2018 Jan 19.

6.

Patient-derived xenografts, a multi-faceted in vivo model enlightening research on rare liver cancer biology.

Moro M, Casanova M, Roz L.

Hepatobiliary Surg Nutr. 2017 Oct;6(5):344-346. doi: 10.21037/hbsn.2017.06.03. No abstract available.

7.

Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness.

Moro M, Bertolini G, Caserini R, Borzi C, Boeri M, Fabbri A, Leone G, Gasparini P, Galeone C, Pelosi G, Roz L, Sozzi G, Pastorino U.

Sci Rep. 2017 Jul 27;7(1):6689. doi: 10.1038/s41598-017-06912-7. Erratum in: Sci Rep. 2018 Feb 27;8(1):3965.

8.

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition.

Pereira C, Gimenez-Xavier P, Pros E, Pajares MJ, Moro M, Gomez A, Navarro A, Condom E, Moran S, Gomez-Lopez G, Graña O, Rubio-Camarillo M, Martinez-Martí A, Yokota J, Carretero J, Galbis JM, Nadal E, Pisano D, Sozzi G, Felip E, Montuenga LM, Roz L, Villanueva A, Sanchez-Cespedes M.

Clin Cancer Res. 2017 Jun 15;23(12):3203-3213. doi: 10.1158/1078-0432.CCR-16-1946. Epub 2017 Mar 16.

PMID:
28302866
9.

Frontal Lobe Decortication (Frontal Lobectomy with Ventricular Preservation) in Epilepsy-Part 1: Anatomic Landmarks and Surgical Technique.

Wen HT, Da Róz LM, Rhoton AL Jr, Castro LH, Teixeira MJ.

World Neurosurg. 2017 Feb;98:347-364. doi: 10.1016/j.wneu.2016.10.090. Epub 2016 Oct 27.

PMID:
27989972
10.

Early Effector T Lymphocytes Coexpress Multiple Inhibitory Receptors in Primary Non-Small Cell Lung Cancer.

Tassi E, Grazia G, Vegetti C, Bersani I, Bertolini G, Molla A, Baldassari P, Andriani F, Roz L, Sozzi G, Pastorino U, Mortarini R, Anichini A.

Cancer Res. 2017 Feb 15;77(4):851-861. doi: 10.1158/0008-5472.CAN-16-1387. Epub 2016 Dec 15.

11.

Metabolic Evaluation of Non-Small Cell Lung Cancer Patient-Derived Xenograft Models Using 18F-FDG PET: A Potential Tool for Early Therapy Response.

Valtorta S, Moro M, Prisinzano G, Bertolini G, Tortoreto M, Raccagni I, Pastorino U, Roz L, Sozzi G, Moresco RM.

J Nucl Med. 2017 Jan;58(1):42-47. doi: 10.2967/jnumed.116.176404. Epub 2016 Oct 20.

12.

Heterotypic paracrine signaling drives fibroblast senescence and tumor progression of large cell carcinoma of the lung.

Lugo R, Gabasa M, Andriani F, Puig M, Facchinetti F, Ramírez J, Gómez-Caro A, Pastorino U, Fuster G, Almendros I, Gascón P, Davalos A, Reguart N, Roz L, Alcaraz J.

Oncotarget. 2016 Dec 13;7(50):82324-82337. doi: 10.18632/oncotarget.10327.

13.

Conversion to stem-cell state in response to microenvironmental cues is regulated by balance between epithelial and mesenchymal features in lung cancer cells.

Andriani F, Bertolini G, Facchinetti F, Baldoli E, Moro M, Casalini P, Caserini R, Milione M, Leone G, Pelosi G, Pastorino U, Sozzi G, Roz L.

Mol Oncol. 2016 Feb;10(2):253-71. doi: 10.1016/j.molonc.2015.10.002. Epub 2015 Oct 22.

14.

Gene Signatures Stratify Computed Tomography Screening Detected Lung Cancer in High-Risk Populations.

Hu J, Boeri M, Sozzi G, Liu D, Marchianò A, Roz L, Pelosi G, Gatter K, Pastorino U, Pezzella F.

EBioMedicine. 2015 Jul 8;2(8):831-40. doi: 10.1016/j.ebiom.2015.07.001. eCollection 2015 Aug.

15.

Complexity in the tumour microenvironment: Cancer associated fibroblast gene expression patterns identify both common and unique features of tumour-stroma crosstalk across cancer types.

Gandellini P, Andriani F, Merlino G, D'Aiuto F, Roz L, Callari M.

Semin Cancer Biol. 2015 Dec;35:96-106. doi: 10.1016/j.semcancer.2015.08.008. Epub 2015 Aug 28. Review.

PMID:
26320408
16.

KAT6B Is a Tumor Suppressor Histone H3 Lysine 23 Acetyltransferase Undergoing Genomic Loss in Small Cell Lung Cancer.

Simó-Riudalbas L, Pérez-Salvia M, Setien F, Villanueva A, Moutinho C, Martínez-Cardús A, Moran S, Berdasco M, Gomez A, Vidal E, Soler M, Heyn H, Vaquero A, de la Torre C, Barceló-Batllori S, Vidal A, Roz L, Pastorino U, Szakszon K, Borck G, Moura CS, Carneiro F, Zondervan I, Savola S, Iwakawa R, Kohno T, Yokota J, Esteller M.

Cancer Res. 2015 Sep 15;75(18):3936-45. doi: 10.1158/0008-5472.CAN-14-3702. Epub 2015 Jul 24.

17.

Comprehensive genomic profiles of small cell lung cancer.

George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan NS, Park KS, Yang D, Karnezis AN, Vaka D, Torres A, Wang MS, Korbel JO, Menon R, Chun SM, Kim D, Wilkerson M, Hayes N, Engelmann D, Pützer B, Bos M, Michels S, Vlasic I, Seidel D, Pinther B, Schaub P, Becker C, Altmüller J, Yokota J, Kohno T, Iwakawa R, Tsuta K, Noguchi M, Muley T, Hoffmann H, Schnabel PA, Petersen I, Chen Y, Soltermann A, Tischler V, Choi CM, Kim YH, Massion PP, Zou Y, Jovanovic D, Kontic M, Wright GM, Russell PA, Solomon B, Koch I, Lindner M, Muscarella LA, la Torre A, Field JK, Jakopovic M, Knezevic J, Castaños-Vélez E, Roz L, Pastorino U, Brustugun OT, Lund-Iversen M, Thunnissen E, Köhler J, Schuler M, Botling J, Sandelin M, Sanchez-Cespedes M, Salvesen HB, Achter V, Lang U, Bogus M, Schneider PM, Zander T, Ansén S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt C, Perner S, Heukamp L, Büttner R, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK.

Nature. 2015 Aug 6;524(7563):47-53. doi: 10.1038/nature14664. Epub 2015 Jul 13.

18.

Microenvironment-Modulated Metastatic CD133+/CXCR4+/EpCAM- Lung Cancer-Initiating Cells Sustain Tumor Dissemination and Correlate with Poor Prognosis.

Bertolini G, D'Amico L, Moro M, Landoni E, Perego P, Miceli R, Gatti L, Andriani F, Wong D, Caserini R, Tortoreto M, Milione M, Ferracini R, Mariani L, Pastorino U, Roato I, Sozzi G, Roz L.

Cancer Res. 2015 Sep 1;75(17):3636-49. doi: 10.1158/0008-5472.CAN-14-3781. Epub 2015 Jul 3.

19.
20.

PARD3 Inactivation in Lung Squamous Cell Carcinomas Impairs STAT3 and Promotes Malignant Invasion.

Bonastre E, Verdura S, Zondervan I, Facchinetti F, Lantuejoul S, Chiara MD, Rodrigo JP, Carretero J, Condom E, Vidal A, Sidransky D, Villanueva A, Roz L, Brambilla E, Savola S, Sanchez-Cespedes M.

Cancer Res. 2015 Apr 1;75(7):1287-97. doi: 10.1158/0008-5472.CAN-14-2444.

21.

Evaluation and validation of a robust single cell RNA-amplification protocol through transcriptional profiling of enriched lung cancer initiating cells.

Rothwell DG, Li Y, Ayub M, Tate C, Newton G, Hey Y, Carter L, Faulkner S, Moro M, Pepper S, Miller C, Blackhall F, Bertolini G, Roz L, Dive C, Brady G.

BMC Genomics. 2014 Dec 17;15:1129. doi: 10.1186/1471-2164-15-1129.

22.

Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction.

Fortunato O, Boeri M, Moro M, Verri C, Mensah M, Conte D, Caleca L, Roz L, Pastorino U, Sozzi G.

Cell Death Dis. 2014 Dec 11;5:e1564. doi: 10.1038/cddis.2014.507.

23.

Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study.

Sozzi G, Boeri M, Rossi M, Verri C, Suatoni P, Bravi F, Roz L, Conte D, Grassi M, Sverzellati N, Marchiano A, Negri E, La Vecchia C, Pastorino U.

J Clin Oncol. 2014 Mar 10;32(8):768-73. doi: 10.1200/JCO.2013.50.4357. Epub 2014 Jan 13. Erratum in: J Clin Oncol. 2014 May 10;32(14):1520.

24.

Surgical anatomy of endoscope-assisted approaches to common aneurysm sites.

Peris-Celda M, Da Roz L, Monroy-Sosa A, Morishita T, Rhoton AL Jr.

Neurosurgery. 2014 Mar;10 Suppl 1:121-44; discussion 144. doi: 10.1227/NEU.0000000000000205.

PMID:
24141479
25.

A prognostic DNA methylation signature for stage I non-small-cell lung cancer.

Sandoval J, Mendez-Gonzalez J, Nadal E, Chen G, Carmona FJ, Sayols S, Moran S, Heyn H, Vizoso M, Gomez A, Sanchez-Cespedes M, Assenov Y, Müller F, Bock C, Taron M, Mora J, Muscarella LA, Liloglou T, Davies M, Pollan M, Pajares MJ, Torre W, Montuenga LM, Brambilla E, Field JK, Roz L, Lo Iacono M, Scagliotti GV, Rosell R, Beer DG, Esteller M.

J Clin Oncol. 2013 Nov 10;31(32):4140-7. doi: 10.1200/JCO.2012.48.5516. Epub 2013 Sep 30.

26.

Surgical treatment of an anterior cranial fossa dural fistula.

Da Róz LM, de Monaco BA, Menendez DF, Casarolli C, Figueiredo EG, Teixeira MJ.

Arq Neuropsiquiatr. 2013 May;71(5):338-9. No abstract available.

27.

Adipose tissue displays trophic properties on normal lung cellular components without promoting cancer cells growth.

Andriani F, Facchinetti F, Furia S, Roz L, Bursomanno S, Bertolini G, Carniti C, Sozzi G, Pastorino U.

J Cell Physiol. 2013 Jun;228(6):1166-73. doi: 10.1002/jcp.24270.

PMID:
23129305
28.

Does the use of DuraSeal in head and spinal surgeries reduce the risk of cerebrospinal fluid leaks and complications when compared to conventional methods of dura mater closure?

Bernardo L, Bernardo WM, Shu EB, Roz LM, Almeida CC, Monaco BA, Figueiredo EG, Sanders FH, Sterman Neto H, Teixeira MJ.

Rev Assoc Med Bras (1992). 2012 Jul-Aug;58(4):402-3. Review. English, Portuguese. No abstract available.

29.

Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells.

Moro M, Bertolini G, Tortoreto M, Pastorino U, Sozzi G, Roz L.

J Biomed Biotechnol. 2012;2012:568567. doi: 10.1155/2012/568567. Epub 2012 Apr 4. Review.

30.

Inactivation of both FHIT and p53 cooperate in deregulating proliferation-related pathways in lung cancer.

Andriani F, Roz E, Caserini R, Conte D, Pastorino U, Sozzi G, Roz L.

J Thorac Oncol. 2012 Apr;7(4):631-42. doi: 10.1097/JTO.0b013e318244aed0.

31.

MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer.

Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, Calabrò E, Croce CM, Pastorino U, Sozzi G.

Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3713-8. doi: 10.1073/pnas.1100048108. Epub 2011 Feb 7.

32.

Molecular cytogenetic characterization of stem-like cancer cells isolated from established cell lines.

Gasparini P, Bertolini G, Binda M, Magnifico A, Albano L, Tortoreto M, Pratesi G, Facchinetti F, Abolafio G, Roz L, Tagliabue E, Daidone MG, Sozzi G.

Cancer Lett. 2010 Oct 28;296(2):206-15. doi: 10.1016/j.canlet.2010.04.009.

PMID:
20435407
33.

The "stem" of chemoresistance.

Bertolini G, Gatti L, Roz L.

Cell Cycle. 2010 Feb 15;9(4):628-9. Epub 2010 Feb 2. No abstract available.

PMID:
20107309
34.

EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration.

Field JK, Liloglou T, Niaz A, Bryan J, Gosney JR, Giles T, Brambilla C, Brambilla E, Vesin A, Timsit JF, Hainaut P, Martinet Y, Vignaud JM, Thunnissen FB, Prinsen C, Snijders PJ, Smit EF, Sozzi G, Roz L, Risch A, Becker HD, Elborn JS, Magee ND, Montuenga LM, Pajares MJ, Lozano MD, O'Byrne KJ, Harrison DJ, Niklinski J, Cassidy A; EUELC Collaborators.

Eur Respir J. 2009 Dec;34(6):1477-86. doi: 10.1183/09031936.00077809.

35.

Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.

Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, Calabrò E, Pastorino U, Sozzi G.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16281-6. doi: 10.1073/pnas.0905653106. Epub 2009 Sep 10.

36.

Plasma DNA levels in spiral CT-detected and clinically detected lung cancer patients: a validation analysis.

Roz L, Verri C, Conte D, Miceli R, Mariani L, Calabro' E, Andriani F, Pastorino U, Sozzi G.

Lung Cancer. 2009 Nov;66(2):270-1. doi: 10.1016/j.lungcan.2009.08.011. Epub 2009 Sep 9. No abstract available.

PMID:
19744743
37.

Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project.

Verri C, Roz L, Conte D, Liloglou T, Livio A, Vesin A, Fabbri A, Andriani F, Brambilla C, Tavecchio L, Calarco G, Calabrò E, Mancini A, Tosi D, Bossi P, Field JK, Brambilla E, Sozzi G; EUELC Consortium.

Am J Respir Crit Care Med. 2009 Mar 1;179(5):396-401. doi: 10.1164/rccm.200807-1153OC. Epub 2008 Dec 18.

PMID:
19096006
38.

Smoking out the cholinergic component in lung cancer.

Paleari L, Russo P, Roz L, Cesario A, Pastorino U.

Clin Cancer Res. 2008 Nov 1;14(21):6742-3. doi: 10.1158/1078-0432.CCR-08-1465. No abstract available.

39.

Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study.

Sozzi G, Roz L, Conte D, Mariani L, Andriani F, Lo Vullo S, Verri C, Pastorino U.

Am J Respir Crit Care Med. 2009 Jan 1;179(1):69-74. doi: 10.1164/rccm.200807-1068OC. Epub 2008 Sep 11.

PMID:
18787214
40.

FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer.

Cortinovis DL, Andriani F, Livio A, Fabbri A, Perrone F, Marcomini B, Pilotti S, Mariani L, Bidoli P, Bajetta E, Roz L, Sozzi G.

Curr Cancer Drug Targets. 2008 Aug;8(5):342-8.

PMID:
18690840
41.

Fragile histidine triad expression in oral squamous cell carcinoma and precursor lesions.

Kujan O, Oliver R, Roz L, Sozzi G, Ribeiro N, Woodwards R, Thakker N, Sloan P.

Clin Cancer Res. 2006 Nov 15;12(22):6723-9.

42.

Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line.

Cavazzoni A, Galetti M, Fumarola C, Alfieri RR, Roz L, Andriani F, Carbognani P, Rusca M, Sozzi G, Petronini PG.

Cancer Lett. 2007 Feb 8;246(1-2):69-81. Epub 2006 Apr 17.

PMID:
16616810
43.

Diadenosines as FHIT-ness instructors.

Campiglio M, Bianchi F, Andriani F, Sozzi G, Tagliabue E, Ménard S, Roz L.

J Cell Physiol. 2006 Aug;208(2):274-81. Review.

PMID:
16547961
44.

Increased sensitivity to cisplatin in non-small cell lung cancer cell lines after FHIT gene transfer.

Andriani F, Perego P, Carenini N, Sozzi G, Roz L.

Neoplasia. 2006 Jan;8(1):9-17.

45.

Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays.

Sozzi G, Roz L, Conte D, Mariani L, Andriani F, Verderio P, Pastorino U.

J Natl Cancer Inst. 2005 Dec 21;97(24):1848-50.

PMID:
16368947
46.

Methylation profile in tumor and sputum samples of lung cancer patients detected by spiral computed tomography: a nested case-control study.

Cirincione R, Lintas C, Conte D, Mariani L, Roz L, Vignola AM, Pastorino U, Sozzi G.

Int J Cancer. 2006 Mar 1;118(5):1248-53.

47.

Reduced FEZ1/LZTS1 expression and outcome prediction in lung cancer.

Nonaka D, Fabbri A, Roz L, Mariani L, Vecchione A, Moore GW, Tavecchio L, Croce CM, Sozzi G.

Cancer Res. 2005 Feb 15;65(4):1207-12.

48.

The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression.

Roz L, Andriani F, Ferreira CG, Giaccone G, Sozzi G.

Oncogene. 2004 Dec 2;23(56):9102-10.

PMID:
15489891
49.

Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line.

Cavazzoni A, Petronini PG, Galetti M, Roz L, Andriani F, Carbognani P, Rusca M, Fumarola C, Alfieri R, Sozzi G.

Oncogene. 2004 Nov 4;23(52):8439-46.

PMID:
15361849
50.

Detecting lung cancer in plasma with the use of multiple genetic markers.

Andriani F, Conte D, Mastrangelo T, Leon M, Ratcliffe C, Roz L, Pelosi G, Goldstraw P, Sozzi G, Pastorino U.

Int J Cancer. 2004 Jan 1;108(1):91-6.

Supplemental Content

Support Center